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Abstract
Background: Malaria in pregnant women has been shown to be associated with low birth weight, stillbirth and
mortality in newborns. The WHO has adopted the use of sulphadoxine-pyrimethamine (SP) to control malaria, a
disease which worsens the plight of pregnant women leading to low birth weight, stillbirths and increased
neonatal mortality. The present study assessed the effectiveness of SP and perception of its use in pregnant
women in Offinso district (Ashanti Region), Ghana.
Method: Pregnant women, gestational age 32 weeks prior to term, were studied from November 2006 to October 2007.
Their haemoglobin levels (Hb), parasitaemia and other quantitative determinants were assessed. In-depth interviews (IDIs)
a n df o c u sg r o u pd i s c u s s i o n s( F G D s )w e r eu s e dt oa s s ess the perception of SP usage and its effectiveness.
Results: Of the 306 study participants, 92 (30%) took one dose, 100 (33%) two doses and 114 (37%) three doses of SP,
respectively. There was significant association between gravidity and SP dosage taken (Pearson c
2 =1 8 . 9 ,p <0 . 0 0 1 ) .
Although adverse effects were produced in 113 (i.e. 37%) of the pregnant women, no significant difference was
observed with regard to the dosage of SP taken (Pearson’s c
2 = 2.3, p ≥ 0.32). Peripheral parasitaemia was present in 47
(15%) of the subjects. There was a poor negative relationship of doses of SP with parasitaemia (r = -0.07, p ≥ 0.24). Mean
Hb was 11.3 ± 1.6 g/dl, with 118 (39%) of the subjects anaemic (Hb < 11.0 g/dl), whilst 187 (61%) were normal (Hb
≥11.0 g/dl). Significant positive correlation of SP use with Hb level (r =0 . 1 5 ,p < 0.008) was observed. SP use reduced
malaria and anaemia prevalence, contributed to reduced maternal morbidity with mild side effects being reported.
Conclusions: This study points to the effectiveness of IPTp using SP as an evidence-based measure for control of
malaria and malaria-related anaemia in pregnancy. Therefore, the Ghana Health Service should improve current
programme strategies to increase the proportion of pregnant women who take three doses of SP, paying attention
to improved face-to-face health education, focussed antenatal care and better social mobilization.
Background
In malaria endemic communities, pregnant women and
children are more vulnerable to malaria infection. Its
effects in pregnancy include chronic anaemia, acute
severe anaemia, miscarriage/forced abortion and pre-
term delivery in the mother, and in the foetus and new-
born; low birth weight, congenital malaria, stillbirth,
perinatal and neonatal deaths [1,2]. In sub-Saharan
Africa, the major detrimental effect of malaria infection
is low birth weight (LBW) and maternal anaemia [1,3,4].
Malaria infection during pregnancy has been estimated
to cause 75,000-200,000 infant deaths each year in stable
transmission areas [3,5].
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the WHO with the use of sulphadoxine-pyrimethamine
(SP) in intermittent preventive treatment of malaria pro-
gramme (IPTp) in pregnancy has been established and
documented in improving birth weight of neonates and
reducing maternal morbidity [1,6-8]. A recent study by
Tutu et al. [9] elucidated on the effect of SP on preg-
nant women and confirmed other studies [4,10-13] that
SP reduces malaria-related anaemia in pregnant women
as compared to those who did not take SP during preg-
nancy. However, the problem of maternal morbidity and
neonatal low birth weights is still persistent in the coun-
try. The present study, therefore, updated information
on the use of SP in IPTp in pregnant women and
assessed the knowledge and the perceptions of its use in
Offinso District, Ghana.
Method
Study area
The study area has been described elsewhere [9], but
briefly, the study was conducted in Offinso District, one
of the 27 administrative districts in the Ashanti Region of
Ghana (Figure 1). The study was carried out in six health
facilities that provide antenatal, delivery and postnatal
services in the district, and communities where these
health centres are situated. The health facilities were St.
Patrick’s Hospital (Offinso), District Assembly Maternal
and Child Health Care Centre (Offinso), Nkenkaasu Hos-
pital, Abofour Health Centre, Akomadan Health Centre
and A.M.E. Zion Health Centre (Afrancho).
Study design and population
The study was an analytical type with a cross-sectional
design. Pregnant women attending antenatal clinic in the
six health facilities and who were 32 weeks of gestation to
term and had taken SP were included in the study. Preg-
nant women with gestational age < 32 weeks irrespective
of their IPTp status were excluded from the study.
Sample size
A sample size of 296 was estimated for the cross sectional
study. The prevalence of anaemia in pregnant women
was 50% [14] and in reducing maternal anaemia by 5%
through the use of SP at the power of 80% and 5% signifi-
c a n c e ,as a m p l es i z eo f2 9 6w a sr e q u i r e df o rt h ec r o s s
sectional study (using Statcalc, Epi info software 2002,
version 6). However, a little over the sample size, 306
data was collected.
Sampling method
Stratified sampling method was used in selecting the
health facilities while convenience (purposeful) sampling
method was used to sample the respondents. The total
number of pregnant women seen yearly in each health
facility was made as a fraction of the total number of
pregnant women seen in all these health facilities
annually. The proportion for each health facility was
used to determine the number of pregnant women to be
sampled from that health facility.
Laboratory investigations and qualitative study
The finger-prick method was used to collect blood for
determination of haemoglobin (Hb) levels and parasitae-
mia as previously discussed [9]. Focus Group Discussions
(FGDs) and in-depth interviews (IDIs) were conducted in
the communities. This qualitative study was undertaken to
assess the knowledge and understanding of study partici-
pants on SP in IPTp programme and possible outcomes of
treatment. Three assemblymen, three chiefs, one queen
mother, an opinion leader as well as nine chemical sellers
in the district were interviewed. Four focus group discus-
sions (FGDs) of “horse shoe” type were conducted with
pregnant women. Two were conducted in Offinso Central
communities and the other two in Akomadan and Afran-
cho communities. The pregnant women were assigned to
one or the other of two categories namely: pregnant
women who were less than twenty years of age and those
who were twenty years or older.
Ethical consideration
Information on the study was provided to the District
Health Administration, the District Assembly and the opi-
nion leaders in the study communities. Permission to
undertake the study was obtained from these stakeholders.
Ethical clearance was sought and obtained from the
Ghana Health Service and the School of Medical Sciences
(SMS) of the KNUST Ethics Committees. Each study par-
ticipant, after being briefed and offered the opportunity to
ask questions about the study, was provided with indivi-
dual informed written consent form to sign or thumbprint.
The written consent forms and participant information
forms were kept separately from the data collection tools.
Definitions and groupings
IPTp was defined as administration of a curative anti-
m a l a r i a lt r e a t m e n td o s eo fS Pa tp r e d e f i n e di n t e r v a l s
(between 16-36 weeks) to asymptomatic pregnant women
during antenatal clinic (ANC), who are at risk of malaria,
regardless of whether or not they are parasitaemic at the
time of visit. Haemoglobin levels (Hb < 11 g/dl) and (Hb <
7 g/dl) in pregnant women were considered as moderate
anaemia and severe anaemia, respectively. Parasitaemia
was defined as the presence of asexual stage parasites in
thick smears. Gravidity was categorized into primigravidae
(women in their first pregnancies), secundigravidae
(women in their second pregnancies) and multigravidae
(women in their third, fourth or more pregnancies) as dis-
cussed in elsewhere in Tutu et al. [9].
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The study participants were given an identification num-
ber, identifying village, house number and a randomly
computer generated digit. All answers were numerically
coded on the questionnaire and laboratory results
entered into Microsoft Office Access, 2003 version. Data
were analysed using Stata version 10.0 (Stata Corporation
4905, Lakeway Drive College Station, Texas 77845, USA).
Averages and 95% confidence interval (CI) were used for
summarizing of results. Frequencies and percentages
Figure 1 Map of Offinso District showing the study towns (Source: Prepared using ArcGIS software, 2008).
Tutu et al. Malaria Journal 2011, 10:385
http://www.malariajournal.com/content/10/1/385
Page 3 of 8were used to compare number of participants associated
with the use of SP, parasitaemia, haemoglobin levels etc.
Analyses of differences in proportions were done using
Pearson’s chi-square test or Fisher’s exact test where
appropriate. Analysis of variance (ANOVA) with Bonfer-
roni measure of comparison was used to measure the dif-
ferences in means and Pearson correlation coefficient
used to determine the relations between variables. For all
statistical tests in this IPTp study, p < 0.05 was consid-
ered significant.
Responses from the qualitative survey were tape-
recorded and transcribed. The data were manually ana-
lysed along defined themes including knowledge of SP
in IPTp and its effects and benefits in preventive treat-
ment of malaria in pregnancy.
Results
Baseline characteristics of the study population
The study recruited 362 pregnant womenof which 56 of
them took no SP and were excluded from the analysis
( F i g u r e2 ) .T h em e a na g eo ft h e3 0 6s t u d yw o m e nw h o
were included in the analysis and took SP (Figure 2) was
27 ± 6 years with a 15 year old being the youngest and a
46 year old, the oldest. Over 50% of the women were
between 20-29 years with less than 10% below 20 years
(Table 1). Primigravidae constituted 18% while secundigra-
vidae and multigravidae made up 24.5% and 57.5% respec-
tively of the study participants. Traders (35.3%) formed
majority of the pregnant women studied. Artisans includ-
ing dressmakers, hair dressers, potters and tie-dyers, made
up 16% of the study women. Civil servants including tea-
chers, nurses, secretaries, etc. made up 3.9% while the
unemployed made up 19% of study women (Table 2).
Property highly owned by the pregnant women was radio
(85.3%), while motorbikes were least (10.1%) owned by
them. Possession of mosquito nets among the pregnant
women was 59.8% with 56.5% being insecticide-treated
nets (ITNs). However, less than 50% of the women slept
in ITNs (Table 2).
The average number of persons per room was 3 ± 1.5
with the least occupant being one and the highest num-
ber of occupants being 13. Twenty eight percent (86
women) lived in houses built with cement blocks and
roofed with aluminium sheets, whilst 72% (220) of them
lived in mud and brick houses with either aluminium
roofing sheets or thatches as roof cover (Table 2).
Seventy four (24%) used traditional medicine which
included preparation of herbs and the bark of trees for
enemata and those added to foods eaten, which they
reported to be helpful as diuretics, for control of nausea
and prevention of constipation. However, these herbs
had no anti-malarial effects.
Use of SP and adverse effects
Nearly a third, 92 (30%) took one dose, 100 (33%) two
doses and 114 (37%) three doses of SP, respectively
 
362 pregnant women recruited 
306 took SP  56 took no SP 
44 (48%) 
had 
anaemia 
72 (63%) 
had normal 
HB 
42 (37%) 
had 
anaemia 
33 (33%) 
had 
anaemia 
48 (52%) 
had normal 
HB 
Included in 
analysis 
92 took one 
dose of SP  
100 took 
two doses 
114 took three 
doses of SP 
67 (67%) 
had normal 
HB 
Figure 2 Trial profile of pregnant women recruited for the study.
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Page 4 of 8(Figure 2). Multigravid women (57.5%) took more doses
of SP as compared to 24.5% and 18% of secundigravid
and primigravid women respectively (Table 3). A little
over a third, 113 (37%) of the pregnant women reported
adverse reactions (including nausea, general malaise,
body weakness, vomiting etc.) with the intake of SP;
however, these effects showed no significant association
with the number of doses of SP taken (Pearson’s c
2 =
2.3, p ≥ 0.32).
Haemoglobin level and SP in pregnant women
The mean haemoglobin (Hb) level was 11.3 ± 1.6 g/dl
(95% CI: 11.1 to 11.4). One hundred and eighteen women
(39%) had moderate anaemia (Hb < 11.0 g/dl) whilst most
of the pregnant women 187 (61%) had normal haemoglo-
bin level (Hb ≥ 11.0 g/dl). There was no significant asso-
ciation between haemoglobin level and gravida of
pregnant women (Pearson’s c
2 =4 ,p ≥ 0.14). Comparing
Hb level with other socioeconomic parameters including
education, occupation, religion, marital status and use of
ITN did not show any significant associations (Pearson’s
c
2 = 0.7, p ≥ 0.9; Pearson’s c
2 =1 . 8 ,p ≥ 0.6; Pearson’s c
2 =
6.1, p ≥ 0.1; Pearson’s c
2 = 1.3, p ≥ 0.3; Pearson’s c
2 = 1.2,
p ≥ 0.3 respectively). There was no significant association
between parasitaemia and haemoglobin level of the preg-
nant women (Fisher’s exact = 0.87).
Haemoglobin level and the doses of SP taken, how-
ever, did show significant association (Pearson’s c
2 =
182.2, p < 0.02). Haemoglobin levels among those who
took various doses of SP did show significant difference
(p < 0.007). By Bonferroni method of comparison, the
haemoglobin level of the pregnant women who took the
first dose of SP was, on average, 0.65 (p < 0.017) and
0.62 (p < 0.019) significantly lower than those who took
the second and third doses of SP, respectively. The hae-
moglobin level of those who took the third dose of SP
was, on average, (0.03) lower than those who took the
second dose of SP but the difference was not significant
(p ≥ 1). However, there was significant positive correla-
tion of SP with haemoglobin level (r = 0.15, p < 0.008).
Parasitaemia and SP in pregnant women
Forty seven (15%) of the pregnant women studied had
parasitaemia. However, there was a weak association
between gravida and parasite density (Pearson’s c
2 =
10.8, p < 0.09). Multigravid women (26/47) were highly
parasitaemic as compared to primigravid (10/47) and
secundigravid women (11/47); nevertheless, parasite
Table 1 Background Characteristics of pregnant women
Age N (306) (%)
≤19 27 (8.82)
20-29 173 (56.54)
30-39 102 (33.33)
≥40 4 (1.31)
Gravida
Primigravidae 55 (18.0)
Secundigravidae 75 (24.5)
Multigravidae 176 (57.5)
Marital Status
Married 149 (48.7)
Single 157 (51.3)
Educational Level
None 76 (24.8)
Primary 67 (21.9)
Middle/J.H.S. 133 (43.5)
Secondary 23 (7.5)
Tertiary 7 (2.3)
Religion
Christian 218 (71.24)
Moslem 75 (24.51)
Traditionalist 13 (4.25)
N = total number of study subjects
Table 2 Socioeconomic status of the pregnant women
Occupation N (306) (%)
Farmer/housewife 79 (25.8)
Trader 108 (35.3)
Artisan 49 (16.0)
Civil servants 12 (3.9)
Unemployed 58 (19.0)
Own Properties
Car 53 (17.3)
Motorbikes 31 (10.1)
Bicycles 155 (50.7)
Radio 261 (85.3)
Television 154 (50.3)
Sleep on bed 264 (86.3)
Windows netted 171 (55.9)
Have mosquito nets 183 (59.8)
Have ITNS 173 (56.5)
Sleep in ITNS 145 (47.4)
Latrine at home 118 (38.6)
Source of drinking water
Pipe borne water 159 (52.0)
Well water 78 (25.5)
Bore-hole water 100 (32.7)
River water 43 (14.0)
Animals kept at home
Goats 54 (17.6)
Sheep 55 (18.0)
Poultry 188 (61.4)
Housing type
Blocks with Al roofing 86 (28.1)
Mud/Bricks with thatches/Al roofing 220 (71.9)
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primigravid women as compared to the secundigravid
women, but the multigravid women recorded none
(Table 4).
Pearson’s correlation showed negative relations of the
parasitaemia level with the number of doses of SP taken
but these were not significant (r = -0.07, p ≥0.24) using
Bonferroni method of comparison.
Knowledge of SP in IPTp and its effects
IDIs conducted with opinion leaders and chemical sell-
ers to obtain information concerning their knowledge
on IPTp showed that many of the chemical sellers did
not have much knowledge on SP-IPTp although they
knew what SP was. FGDs with pregnant women also
revealed that few of them really knew which drug they
were taking and why they took it.
“I have heard about that one and some of them even
come here to buy it because when it was given to
them in the hospital they realized it was good”... we
know it as Fansidar and in the hospital it’s Mala-
fan”. [Chemical seller, Aboasu]
“Yes. I heard that they are made to take it right there
for 3 times. So if a pregnant woman does not attend
the antenatal clinic and faces any complications then
it is her own problem”. [Chemical seller, Afrancho]
“A doctor from Offinso came to talk to us about it and
I think they take it for 3 times before delivery and it is
helping them because I have not heard of premature
birth since it started”. [Queen mother of Afrancho]
When a chemical seller was asked whether he had
heard about SP, he said he had not heard much about
it. “I heard that the pregnant women go to the hospital
for some chloroquine tablets“. [Chemical seller, Offinso]
This also shows that some people are still ignorant
about what is happening in relation to using SP in IPTp.
A pregnant woman added: “When you are four
months old and you feel the baby quickening, she, the
n u r s e ,g i v e sy o uad r u gt h a tw i l lp r o t e c tb o t ht h e
mother and the baby from malaria. And you are to
take the drug every month for three times“.[ F G D ,p r e g -
nant women]
Most of the chemical sellers knew about Fansidar
®
and Malafan
® but did not know much about SP use in
IPTp. Some also did not know that Fansidar
® is the
same as SP. The information gathered indicated that
the pregnant women did not observe any major adverse
effects associated with intake of SP. The adverse effects
mentioned, however, and which were considered minor
were vomiting, nausea and body weakness with isolated
cases of itching and palpitation. “When I took the drug,
I vomited and became very weak”. [FGD, pregnant
women]
Some of the pregnant women said they experienced
minor problems such as nausea, vomiting, body weakness
etc. when they took it for the first time but with the sub-
sequent doses they did not experience any adverse
effects. “When I took the first dose, I vomited but with the
second dose I did not. She, (the midwife) told me to con-
tinue taking it. And before I took the drug someone had
already explained to me that with the first dose you can
vomit or become weak. So I was aware before coming in
for the drug”. [FGD, pregnant women]
Another pregnant woman added: “When I took the
first dose, I was bodily weak, nauseous and even vomited
later on, but when I took the second dose nothing hap-
pened”. [FGD, pregnant women] “Id i d n ’t vomit when I
took the first dose but with the second dose and the third
dose, I vomited”.[ F G D ,p r e g n a n tw o m e n ]“When I took
the first dose, I felt weak and lost appetite”. [FGD, preg-
nant women] “If e l tw e a ka n dt h i sc o n t i n u e dw h e nI
took the second dose but I told the midwife about it and
she encouraged me to take the third dose”.[ F G D ,p r e g -
nant women]
Table 4 Parasite density (per μl of blood) of pregnant women
Gravida None Parasite density (per μl of blood) Total
1-1999 2000-4999 > = 5000
Primigravida 45 (17.4%) 6 (15.0%) 1(33.3%) 3 (75.0%) 55 (18.0%)
Secundigravida 64 (24.7%) 9 (22.5%) 1(33.3%) 1 (25.0%) 75 (24.5%)
Multigravida 150 (57.9%) 25 (62.5%) 1 (33.3%) 0 (00.0%) 176 (57.5%)
Total (100%) 259 (100.0%) 40 (100.0%) 3 (100.0%) 4 (100.0%) 306 (100.0%)
Table 3 Doses of SP taken by pregnant women
Gravida Dose 1 Dose 2 Dose 3 Total
Primigravida 12 (13.04%) 27 (27.0%) 16 (14.0%) 55 (18.0%)
Secundigravida 13 (14.13%) 27 (27.0%) 35 (30.7%) 75 (24.5%)
Multigravida 67 (72.83%) 46 (46.0%) 63 (55.3%) 176 (57.5%)
Total (100%) 92 (100.0%) 100(100.0%) 114(100.0%) 306(100.0%)
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The IDIs and FGDs revealed that the IPTp programme
was effective. Most of the respondents admitted that the
rate at which the pregnant women reported sick had
reduced. They also admitted that the benefits of IPTp
for mothers also extends to their unborn babies, “It pro-
tects us from getting malaria and anaemia”. [FGD, preg-
nant women] “It has some benefits because now we
hardly hear complications in pregnancy and it has also
reduced stillbirths“. [Chemical seller, Akomadan].
In-depth interviews indicated that IPTp with SP had
benefited pregnant women and their babies since they
hardly contracted malaria and the birth weights of their
babies had improved. One chief said “Yes, only if the preg-
nant women will follow the instructions and take it”
[Chief of Aboasu].
Discussion
Malarial infection during pregnancy increases the risks of
severe sequelae for the pregnant woman and the risk of
delivering a low birth weight baby. The present study
showed that the IPTp with SP programme is helpful in
reducing malaria-related maternal anaemia and P. falci-
parum parasitaemia in pregnant women as discussed by
various studies and reports [1,6,9,10,15,16]. Increased
doses of SP were associated with increased Hb levels
which do confirm the previous study done [9]. Among the
gravida in the pregnant women, Hb level did not show any
significant association with use of SP and thus, nearly two
third, 61% of them had normal Hb level (Hb ≥11.0 g/dl)
with no recording of severe anaemia (Hb < 7 g/dl). This
however, contradicts the previous study [9] significant
association of Hb level with gravidity since not all the
study participants did take SP. Thus, the use of SP in preg-
nancy improves Hb levels in them.
There was reduced parasitaemia 15% (47/306) in the
pregnant women, which could be attributed to the
increased doses of SP taken. The SP negatively correlated
with parasitaemia but was not significant (r = -0.07,
p ≥0.24). In the qualitative studies however, SP was com-
mented on to protect against malaria-related anaemia in
pregnancy; “It protects us from getting malaria and anae-
mia"; said one pregnant woman in the FGD “Yes, only if
the pregnant women will follow the instructions and take
it” commented a chief. Though parasitaemia was high
among the multigravidae as compared to the secundigravi-
dae and primigravidae, the primigravid women recorded
higher parasite densities (≥5000 per μlo fb l o o d )a sc o m -
pared to secundigravid and multigravid pregnant women.
This indicates the high susceptibility of the primigravid
women to malaria and possible development of parasite
resistance to the SP as reported in the previous study [9].
There were lots of chequered reactions on taking the
doses of SP as commented by some of the pregnant
women in the FGD: “When I took the first dose, I was
bodily weak, nauseous and even vomited later on, but
when I took the second dose nothing happened"; “Id i d n ’t
vomit when I took the first dose but with the second dose
and the third dose, I vomited”.; “When I took the first
dose, I felt weak and lost appetite”. However, these
adverse effects were not serious enough to pick up on SP
in pregnancy and not significant with the number of
doses of SP taken, hence, supports the mild effects of SP
reported in other studies [1,9,10,15,17].
SP use as a preventive treatment drug for malaria in
pregnancy was not well known among the people in the
communities (particularly the chemical sellers) and, thus,
they were less informed and educated about it “Ih a v e
heard about that one and some of them even come here
(the drug store) to buy it because when it was given to
them in the hospital they realized it is good”, “... we know
it as Fansidar and in the hospital it’s Malafan”.
A comment from one chemical seller: “I heard that the
pregnant women go to the hospital for some chloroquine
tablets“ indicates that most of the people are less knowl-
edgeable about the use of SP in the IPTp and not following
the instructions on administering the drug could lead to
abuse by pregnant women and the subsequent resistance
of the malaria parasite to it. However, majority of the
respondents (especially the pregnant women) were aware
of IPTp with SP and its benefits, including reduction of
maternal morbidity and stillbirths, improved weights of
babies “It protects the mother and the baby against malaria
infection” said a pregnant woman in the FGD; “It makes
both the mother and the baby to be healthy” said another
pregnant woman in the FGD. They normally get educated
on the IPTp during visits to antenatal clinics and at com-
munity durbars and electronic media including radio of
which majority, 85% of the women owned.
In spite of the little or no formal education, low socioe-
conomic status and poor housing units of most (72%) of
the pregnant women with over 60% being traders and
farmers, the patronage of SP in IPTp was good and
higher among multigravid women (58%) as compared to
the secundigravid (24%) and primigravid women (18%).
T h el o wp a t r o n a g eb yt h ep r i m i g r a v i dw o m e na sf o u n d
in the previous studies [9] is discouraging since they are
the vulnerable group with high maternal morbidity and
low birth weight deliveries [2,13,18,19].
Study limitations
Helminthic infection, malnutrition and other disease
conditions could contribute to anaemia in pregnancy [9]
aside malaria, and these were not determined. For the
purpose of this study, SP doses administered to the
pregnant women were obtained from the ANC cards at
the health facilities, and possible non-recording of doses
might have led to an underestimation of doses received.
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venting mosquito bites was quite encouraging since over
50% of the pregnant women studied had ITNs although
less than 50% admitted usage of the nets. However, the
use of ITNs by the pregnant women in combination with
the IPTp programme was not assessed since there were
chequered responses to the use of the nets. However,
these are not expected to significantly influence the
observed findings.
Conclusions
Results of the present study, thus, suggest that effective
implementation of the IPTp using SP is an evidence-
based measure for control of malaria-related anaemia in
pregnancy. Reduced maternal anaemia impacts positively
on both maternal and neonatal health. The Ghana
Health Service should, therefore, design and implement
interventions to increase the proportion of pregnant
women (especially primigravid women) who take the
recommended three doses of SP during pregnancy.
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